Alliance Global Partners analyst James Molloy raised the firm’s price target on CNS Pharmaceuticals (CNSP) to $7 from $4 pre-reverse-split and keeps a Buy rating on the shares after the company announced Q1 results and a quarterly update last week. The company recently pivoted to focusing on its TPI-287 candidate for Glioblastoma Multiforme after its lead candidate berubicin failed to meet the primary endpoint of a pivotal Phase 2 trial, notes the analyst, who is removing berubicin from the firm’s valuation. The firm, which notes that CNS executed a 50:1 reverse split in Q1, values TPI-287 at $5.25 per share and cash and technology at $1.75 per share.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNSP:
- CNS Pharmaceuticals reports Q1 EPS ($1.58) vs. ($1,020.48) last year
- CNS Pharmaceuticals sees cash runway into 2h26
- CNS Pharmaceuticals Raises $5M in Public Offering
- CNS Pharmaceuticals acquires Orphan Drug Designation for TPI 287
- CNS Pharmaceuticals files to sell 5.22M shares of common stock, warrants
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue